| abstract |
Combination of at least two active antiviral agents, and ribavirin but not interferon, for use in the treatment of HCV. The present invention features combinations of antiviral agents for use in therapies with ribavirin but without interferon in the treatment of HCV. Preferably, the treatment is for a short time, such as no more than 12 weeks. In one aspect, the use of combinations of antiviral agents in therapies comprises administering at least two direct-acting antiviral agents comprising an HCV polymerase inhibitor and an HCV NS5A inhibitor and ribavirin to a subject with HCV infection. |